Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer.

Journal: Annals of translational medicine
Published Date: Dec 1, 2019

Abstract

BACKGROUND: As deregulation of androgen receptor (AR) signaling target genes is associated with tumorigenesis and the development of prostate cancer (PCa), AR signaling is the primary therapeutic target for PCa. Although patients initially responses to first-line androgen deprivation therapies (ADTs), most of them with advanced PCa progress to lethal castration-resistant prostate cancer (CRPC). Recent studies have suggested the molecular mechanisms by which AR elicit the robust up-regulation of the gene. We suggest that restored expression of gene, modulated by androgen receptor splicing variant 7 (AR-V7) which replaces full length androgen receptor (AR-FL) in androgen ablation status, promotes CRPC progression through activating NF-κB signaling.

Authors

  • Jianpeng Yu
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Libin Sun
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Tangxi Hao
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Boya Zhang
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Xuanrong Chen
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Hanlin Li
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Zheng Zhang
    Key Laboratory of Sustainable and Development of Marine Fisheries, Ministry of Agriculture and Rural Affairs, Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao, PR China.
  • Shimiao Zhu
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Changyi Quan
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Yuanjie Niu
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
  • Zhiqun Shang
    Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals